🇺🇸 FDA
Pipeline program

DTX301

DTX301-CL301

Phase 3 gene_therapy active

Quick answer

DTX301 for OTC Deficiency is a Phase 3 program (gene_therapy) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
OTC Deficiency
Phase
Phase 3
Modality
gene_therapy
Status
active

Clinical trials